A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal

Alcoholism: Clinical and Experimental Research

Volumn 33, Issue 9, 2009, Pages 1582-1588

  Myrick, Hugh ^a,b,c   Malcolm, Robert ^b   Randall, Patrick K ^b   Boyle, Elizabeth ^b   Anton, Raymond F ^b   Becker, Howard C ^a   Randall, Carrie L ^b  

^a MUSC Medical Center   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alcohol dependence; Alcohol withdrawal; Gabapentin; Lorazepam

Indexed keywords

DIPHENHYDRAMINE; GABAPENTIN; LORAZEPAM;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY; ARTICLE; BREATH ANALYSIS; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG INTOXICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PRIORITY JOURNAL; PROBABILITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SCORING SYSTEM; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URTICARIA; VERBAL BEHAVIOR; WITHDRAWAL SYNDROME;

ADULT; ALCOHOL DRINKING; AMINES; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; HYPNOTICS AND SEDATIVES; LORAZEPAM; MALE; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 69249106941     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2009.00986.x     Document Type: Article

References (39)

1. Anton RF (1999) What is craving? Models and implications for treatment. Alcohol Res Health 23 : 165 173.
2. Baydas G, Sonkaya E, Tuzcu M, Yasar A, Donder E (2005) Novel role of gabapentin in neuroprotection of central nervous system in strepozotocine- induced diabetic rats. Acta Pharmacol Sin 26 : 417 422.
3. Beck AT, Ward CH, Mendlesohn M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4 : 561 571.
4. Bisaga A, Evans SM (2006) The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug 83 : 25 32.
5. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA (2008) A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomia. Alcohol Clin Exp Res 32 : 1429 1438.
6. Cho SW, Cho EH, Choi SY (1998) Activation of two types of brain glutamate dehydrogenase isoproteins by gabapentin. FEBS Lett 426 : 196 200.
7. Ciraulo DA, Sands BF, Shader RI (1998) Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psychiatry 145 : 1501 1506.
8. Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC (2007) Functional biology of the a2d subunits of voltage-gated calcium channels. Trends Pharmacol Sci 2895 : 220 228.
9. Fernandez MC, Walter FG, Petersen LR, Walkotte SM (1996) Gabapentin, valproic acid, and ethanol intoxication: elevated blood levels with mild clinical effects. J Toxicol Clin Toxicol 34 : 437 439.
10. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structures Clinical Interview for DSM-IV Axis I disorders (SCID-I) (clinical version). American Psychiatric Publishing Inc., Washington, DC.
11. Furieri FA, Nakamura-Palacios EM (2007) Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68 : 1691 1700.
12. Garofalo E, Koto E, Feuerstein T, Goedecke AG (1993) Experience with gabapentin overdose: five case studies. Epilepsia 349 (Suppl. 2 157.
13. Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN (1996) The novel anticonvulsant drug, gabapentin (Neurontin), binds to the a2d subunit of a calcium channel. J Biol Chem 271 : 5768 5776.
14. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14 : 540 545.
15. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345 : 1734 1739.
16. Letterman L, Markowitz JS (1999) Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. Pharmacotherapy 19 : 565 572.
17. Littleton J (1998) Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World 22 : 13 24.
18. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballanger JC (2002) The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 5 : 349 355.
19. Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 28 : 51 63.
20. Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP (2006) A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict 15 : 76 84.
21. Mayo-Smith MF (1997) Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 278 : 144 151.
22. McLean MJ (1994) Clinical pharmacokinetics of gabapentin. Neurology 44 (6 Suppl. 5 S17 S22 discussion S31-2.
23. Myrick H, Anton R, Voronin K, Wang W, Henderson S (2007) A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res 31 : 221 227.
24. Myrick H, Malcolm R, Anton RF (2003) The use of anticonvulsants in the treatment of addictive disorders. Prim Psychiatry 10 : 59 63.
25. Myrick H, Malcolm R, Brady KT (1998) Gabapentin treatment of alcohol withdrawal [letter]. Am J Psychiatry 155 : 1632.
26. Myrick H, Malcolm R, Henderson S (2002) Three doses of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res 26 (Suppl. 5 129A.
27. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH (1996) The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 39 : 95 99.
28. Pittenger C, Desan PH (2007) Gabapentin abuse and delirium tremens upon gababpentin withdrawal. J Clin Psychiatry 68 : 483 484.
29. Poulos CX, Zack M (2004) Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers. Behav Pharmacol 14 : 503 512.
30. Pugsley TA, Whetzel SZ, Dooley DJ (1998) Reduction of 3,4-diaminopyridine-induced biogenic amine synthesis and release in rat brain by gabapentin. Psychopharmacology 137 : 74 80.
31. Skinner HA, Allen BA (1982) Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91 : 199 209.
32. Sobell LC, Sobell MB, Leo GI, Cancill A (1998) Reliability of a timeline method:assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 83 : 393 402.
33. Stout RL, Wirtz PW, Carbonari JP, Del Boca FK (1994) Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol 12 (Suppl. 70 75.
34. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989) Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-AR). Br J Addict 84 : 1353 1357.
35. Taylor CP (1998) Mechanisms of action of gabapentin. Drugs Today 34 (Suppl. D 3 11.
36. Victorri-Vigneau C, Guerlais M, Jollient P (2007) Abuse dependency and withdrawal with gabapentin: a first case report. Pharmacopsychiatry 40 : 43 44.
37. Voris J, Smith NL, Rao SM, Thorne DL, Flowers QJ (2003) Gabapentin for the treatment of ethanol withdrawal. Subst Abuse 24 : 129 132.
38. Watson WP, Robinson E, Little HJ (1997) The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharmacology 36 : 1369 1375.
39. Zung WW (1971) A rating instrument for anxiety disorders. Psychosomatics 12 : 371 379.